Expert: Exclusivity of biotech drugs will not hamper competition

11/29/2009 | Boston Globe (tiered subscription model), The

Data exclusivity provided to biotech medicines does not prevent competition as long as generic-drug companies conduct their own safety and effectiveness research to launch their products, said Robert K. Coughlin, president of the Massachusetts Biotechnology Council, in response to a Boston Globe editorial. A health reform provision that would give 12 years of protection to brand-name biotech drugs would expand access to treatments and encourage innovation, and should not be compared to exclusivity given to traditional pharmaceuticals, Coughlin said.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC